Promoter holding
64.27%
BP
Bigtec Private Limited - Due diligence report
A 360° intelligence report on Bigteclabs: trust score, financial health, credit view, compliance, directors, growth and distress signals - g…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Bigteclabs — 360° Intelligence Report
Generated from MCA filings & public records59/100
Trust Score
Moderate
Bigteclabs is assessed as Moderate with a Trust Score of 59/100. Bigteclabs is an active private limited indian non-government company incorporated in 1996, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and high financial risk profile.
Report generated on 14 Jul 2026 from the latest processed filings. Bigtec Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
59/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
38/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
40/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- No open charges - unencumbered balance sheet.
- Moderate gearing (D/E 1.42).
Charges position: 0 open (-) · 7 satisfied (159.56 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 1 | 48.0 cr |
| Canara Bank | 3 | 48.0 cr |
| Karur Vysya Bank Limited | 1 | 48.0 cr |
| Department Of Biotechnology | 1 | 48.0 cr |
| The Karur Vysya Bank Limited | 1 | 48.0 cr |
Compliance Score: 38/100 Caution Indicated
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: RBI.
- Litigation present in 2 court forum(s).
- 1 auditor resignation(s) filed - latest: T.S DEVADAS & CO on 2021-03-23.
- Delayed payments to MSME suppliers disclosed (4 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| CHANDRASEKHAR BHASKARAN NAIR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SRIRAM NATARAJAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANGEETHA SRIRAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Molbio Diagnostics Private Limited
Subsidiaries
-
Group entities
1
Capital events
2 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Molbio Diagnostics Private Limited | Holding Company | 74.00% |
| Bigtec Healthcare Private Limited | Associate Company | 74.00% |
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 70 · Distress 60
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Operating for 30+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Compliance score is weak (38/100).
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 1.08 Lakh.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence51/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment46/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view57/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events08 Aug 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
23 Feb 2023
Director ceased
ROHIT ASHOK KUMAR MULLANGI
26 Jul 2021
Charge satisfied
Others
24 Jun 2021
Director ceased
GOPALKRISHNA MANGALORE KINI
22 Jan 2021
Charge satisfied
Department Of Biotechnology
30 Dec 2020
Director ceased
SRIRAM NATARAJAN
Director ceased
SANGEETHA SRIRAM
24 Dec 2020
Director appointed
SRIRAM NATARAJAN (Director)
Director appointed
SANGEETHA SRIRAM (Director)
02 Nov 2020
Director ceased
GOPALAKRISHNA SAMPATHGIRI
18 Jul 2020
Director ceased
NILESHWAR DAMODAR PRABHU
22 Jan 2020
Director ceased
ROHIT BRIJMOHAN MANTRI
20 Jan 2020
Charge created
Others - 140.00 cr
04 Jul 2017
Charge satisfied
The Karur Vysya Bank Limited
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 7 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Itc Labs | U74999HR2016PTC058170 | Panchkula, Haryana, India |
| Scitus | U74999TN2017PTC118805 | Chennai, Tamil Nadu, India |
| Proteogen Biosciences (India) Private Limited | U51109KA2011PTC058876 | Bengaluru, Karnataka, India |
| Symbiotic Sciences | U73100DL2007PTC159662 | New Delhi, Delhi, India |
| Hari Shankar Singhania Elastomer And Tyre Research Institute | U73100RJ1991NPL006245 | Rajasthan, Rajasthan, India |
| Enveda Therapeutics India Private Limited | U73100AP2019FTC112638 | Visakhapatnam, Andhra Pradesh, India |
| Sskbio | U74900TG2013PTC090263 | Hyderabad, Telangana, India |
| Popvax | U73100MH2021PTC364588 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Bigteclabs before audits and certifications: compliance score 38/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Bigteclabs: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Bigteclabs - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 59/100, distress signals and MSME payment-delay disclosures - know whether Bigteclabs pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Bigteclabs - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Bigteclabs an active company?
Bigteclabs has MCA status “Active” with a compliance score of 38/100 (Caution Indicated).
Is Bigteclabs financially healthy?
Bigteclabs has a Financial Health Score of 40/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Bigteclabs?
Its overall Trust Score is 59/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Bigteclabs?
The ultimate holding entity is Molbio Diagnostics Private Limited. 3 active director(s) are on record.
Does Bigteclabs have loans or charges against its assets?
No open charges - all 7 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Bigteclabs up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 38/100 (Caution Indicated).
Is it risky to lend to Bigteclabs?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
